[Urogenital symptoms and possibilities for urological intervention in the palliative care situation].
During the course of malignancies of nearly all tumor entities the urogenital organs are frequently influenced. The resulting disorders are subsumed under the term"urogenital symptoms". Especially with the goal of improving quality of life these symptoms have to be treated with respect. In addition further therapeutic measures, e.g. the application of a palliative chemotherapy, makes an unobstructed urinary excretion necessary. This article gives an overview of the indications for treating urogenital symptoms and contrasts different therapy concepts.
Jäger
T
T
Klinik für Urologie, Universitätsklinikum, 45122 Essen. tobias.jaeger@uni-due.de
Schenck
M
M
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D042241:Early Diagnosis; D005260:Female; D052776:Female Urogenital Diseases / Q000175:diagnosis / Q000523:psychology / Q000628:therapy*; D006801:Humans; D006869:Hydronephrosis / Q000175:diagnosis / Q000523:psychology / Q000628:therapy; D008297:Male; D052801:Male Urogenital Diseases / Q000175:diagnosis / Q000523:psychology / Q000628:therapy*; D010166:Palliative Care; D011788:Quality of Life; D013165:Splints; D014517:Ureteral Obstruction / Q000175:diagnosis / Q000523:psychology / Q000628:therapy; D014546:Urinary Catheterization; D014555:Urination Disorders / Q000175:diagnosis / Q000523:psychology / Q000628:therapy; D014565:Urogenital Neoplasms / Q000150:complications* / Q000523:psychology / Q000628:therapy
D000970:Antineoplastic Agents